Neutra Corp. (OTCBB: NTRR) announced today that clinical trials are proceeding as planned on two new supplements that the company hopes will help it carve out a foothold in the booming global market for all-natural male enhancement products.

NTRR initiated the first round of clinical testing on the supplements late last month. The trials are part of NTRR's strategy to produce a safer, non-prescription alternative to popular male enhancers such as Viagra, which can carry potentially serious side effects. Clinical trials will be crucial to the process of fine-tuning the new formulas.

"We're pleased with what we've seen so far in these clinical trials, and we plan to push forward until we achieve the results we want," said NTRR CEO Michael-Shane Henderson. "We believe we're very close to perfecting an all-natural formula that both men and women will love. Side effects don't belong in the bedroom, and we're working hard to make sure we deliver a product that's safe and effective."

Neutra Corp. is developing innovative, all-natural products to compete in the fast-growing nutraceuticals industry alongside Herbalife Ltd. (NYSE: HLF), Vitamin Shoppe (NYSE: VSI), Nutraceutical International Corp. (NASDAQ: NUTR) and Schiff Nutrition International Inc. (NYSE: WNI).

For more information on NTRR's nutraceuticals initiative, please visit www.neutracorp.com/investors.

Follow NTRR on Twitter at www.twitter.com/neutracorp.

About Neutra Corp.

Neutra Corp. (www.neutracorp.com) is a healthy lifestyle company that specializes in the development and marketing of nutritional supplements, nutrient boosters, herbal remedies and other natural wellness solutions. The company is currently working to produce a full range of products to address every component of a healthy lifestyle, including muscle building, weight loss and general wellness through a daily nutrition regimen. For investing information and performance data, please visit www.neutracorp.com/investors.

Notice Regarding Forward-Looking Statements

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words "believes," "expects," "anticipate" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the company to differ materially from those expressed or implied by such forward-looking statements. In addition, description of anyone's past success, either financial or strategic, is no guarantee of future success. This news release speaks as of the date first set forth above and the company assumes no responsibility to update the information included herein for events occurring after the date hereof.